Download
1 / 3
30 likes | 46 Views
Market Research Future (MRFR)’s latest study asserts that the global Market is set to expand at a CAGR of XX% during the forecast period 2018 to 2023. The global market is set to reach a value over USD XX.xx Mn by 2023.
E N D
www.marketresearchfuture.com Addison’s Disease Market Research Report-Global Forecast till 2023 P a g e | 1 Copyright © 2017 Market Research Future.
www.marketresearchfuture.com Global Addison's Disease Market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 168 million in 2017 and is projected to grow at a CAGR of 10.4% over the forecast period. Addison's disease is a disorder which occurs when the body produces scarce amounts of specific hormones produced by the adrenal glands. Pfizer Inc., Boehringer Ingelheim International GmbH, Shire, Tocris Bioscience, GlaxoSmithKline plc, Merck KGaA, Lupin Pharmaceuticals, Inc., Abbott, Amgen Limited & Amgen Ireland Limited, Bayer AG, Biogen, Eli Lilly and Company, Novartis AG, Diurnal, Switzer Life science Pvt. Ltd. are some of the key players in the global Addison's disease market. However, lack of awareness and inability to diagnose the disease in early stages can hamper the market growth over the forecast period. Browse Complete Premium Research Report Enabled with Respective Tables and Figures at https://www.marketresearchfuture.com/reports/addison-s-disease-market-6628 Global Addison’s Disease Market has been segmented into diagnosis, treatment and end user. The market, on the basis of diagnosis, has been segmented into laboratory tests and imaging tests. Laboratory tests have been further segmented into blood tests, ACTH stimulation tests, insulin-induced hypoglycemia test, and other tests. Blood tests are expected to hold the largest market share owing to their high effectiveness to diagnose the disease and preference among the physicians. ACTH stimulation test is expected to be the fastest growing market due to the low cost of the diagnosis method. Imaging tests have been segmented into chest radiography and CT scan. The market, by treatment, has been segmented into oral corticosteroids and corticosteroids injections. The market, by end user, has been segmented into hospitals & clinics, diagnostic laboratories, and other end users. The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Addison’s disease market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European Addison’s disease market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The Addison’s disease market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Addison’s disease market in the Middle East & Africa has been segmented into the Middle East and Africa. Avail Sample Copy for this Report https://www.marketresearchfuture.com/sample_request/6628 Geographically, the Americas is anticipated to dominate the global Addison's disease market owing to a well- developed healthcare sector and the rising prevalence of the disease. According to a report published by the Centers Medicare and Medicaid Services in April 2018, National Healthcare Expenditure grew by 4.3% to USD 3.3 trillion in 2016 from the previous year. P a g e | 2 Copyright © 2017 Market Research Future.
www.marketresearchfuture.com P a g e | 3 Copyright © 2017 Market Research Future.
